Health Canada has approved MSD's anti-programmed cell death protein 1 (PD-1) therapy Keytruda for treating adults with ...

Merck & Co is pressing home its precious advantage in first line non-small cell lung cancer, with new data from a Keytruda + chemo combination suggesting patients' lives could be significantly ...

But MSD will have to play its cards right to gain access to England’s lung cancer market – as Keytruda received its own draft rejection in second line NSCLC two weeks ago. Speaking to ...

Analysts covering Merck predict earnings growth of 17.6% in 2025 and an additional 10.4% increase in 2026. With shares currently trading at seven times forward 2025 earnings, Merck appears to be an ...

Moments after Regeneron CEO Len Schleifer scolded analysts for asking too many questions about the disappointing sales of eye ...

Nuvation has a best-in-class lung cancer drug that could be approved in the US in June. Read why I'm bullish on the stock ...

Over 230 patients enrolled in potential registration-enabling trial in 1L HLA-A2-negative MUM, and median PFS readout targeted by year-end 2025 95 patients enrolled ...

Merck plans to stop a late-stage study testing its drug to treat pulmonary arterial hypertension (PAH) ahead of time based on strong efficacy shown in previous studies, the drugmaker said on Thursday.

Few companies in the biotech industry have performed better in the past two years than Summit Therapeutics (NASDAQ: SMMT).

Merck's Keytruda generates over $20 billion in sales ... True, one of its most important indications is in non-small cell lung cancer (NSCLC), and it is in this market that ivonescimab, a ...

Pembrolizumab (Keytruda, Merck Sharp & Dohme) is indicated for 'the adjuvant treatment of adults with non-small cell lung carcinoma who are at high risk of recurrence following complete resection and ...